SCM Lifescience

SCM Lifescience

SCM Lifescience was established by a Korean family with wealth built through manufacturing and diversified holdings — the firm has not publicly disclosed founder names or founding year. The entity maintains a distributed footprint across Incheon (HQ), Seoul, New York, and Rockville, Maryland, positioning itself as a translational bridge between Asian capital and Western biomedical innovation. The firm's strategy spans company creation, direct equity in private and public biotech companies, and therapeutic development. Known areas of focus include rare disease, oncology, CNS disorders, and immunotherapy — tracked through public records of portfolio companies such as SCM Biotech (a Korean cell and gene therapy developer) and U.S. partners involved in early-stage neurology assets. SCM Lifescience also invests in platform technologies like AI-driven drug discovery and biomarker diagnostics. The geographic scope centers on South Korea and the U.S., with secondary exposure to European academic spinouts. Total assets under management are undisclosed. Team size is not public; the firm maintains a lean executive structure typical of single-family offices. Adjacent vehicles have not been identified. No major operational event from the last 24 months could be independently verified from public records. The firm's structural differentiator is hybrid — it operates not only as an allocator but as a sponsor and co-developer of therapeutics. The family office maintains its own R&D pipeline, blurring the line between investor and drug developer. This model, rare among Asian family offices, allows it to take IP risk that most institutional life-sciences funds avoid.